In a major development for India’s pharmaceutical and healthcare sectors, the expiry of Danish drugmaker Novo Nordisk’s patent on semaglutide—the key ingredient in blockbuster drugs like Ozempic and Wegovy—has paved the way for a wave of affordable generic alternatives. The move is expected to significantly transform access to weight-loss and diabetes treatments across the country.
Semaglutide, a GLP-1 receptor agonist, has gained global prominence for its effectiveness in managing type 2 diabetes and aiding weight loss. However, its high cost has limited accessibility in India, where a large portion of the population remains price sensitive. With the patent expiring in March 2026, Indian pharmaceutical companies are now free to manufacture and market generic versions of the drug.
Industry estimates suggest that more than 40 domestic drugmakers are preparing to launch over 50 generic versions, intensifying competition in the market. These generics are expected to be priced significantly lower—potentially reducing monthly treatment costs from upwards of ₹10,000 to as low as ₹1,500–₹5,000, with some estimates placing prices even lower depending on dosage and brand.
Indian pharmaceutical firms have already begun capitalising on this opportunity. Hyderabad-based Natco Pharma, for instance, has announced the launch of its semaglutide injection at a fraction of the original cost, positioning itself as an early entrant in the generics market. Other major players such as Sun Pharma, Dr Reddy’s Laboratories, Cipla, and Lupin are also expected to follow suit, further expanding the availability of these therapies.
The patent expiry is being widely viewed as a turning point for public health in India, a country often referred to as the “diabetes capital of the world.” With rising obesity rates and lifestyle-related disorders, access to affordable GLP-1 therapies could play a critical role in disease management. Experts believe that the increased availability of low-cost generics will broaden the patient base and improve treatment adherence.
At the same time, the influx of generic versions raises certain regulatory and safety concerns. Analysts have warned that an overcrowded market could lead to confusion among patients and healthcare providers, particularly with multiple brands offering similar formulations. There are also apprehensions regarding misuse, especially if the drugs are marketed as lifestyle or cosmetic solutions rather than prescription medications.
From a commercial standpoint, the development is expected to intensify competition not only among domestic manufacturers but also for global pharmaceutical giants. Novo Nordisk, which previously enjoyed a dominant position in the segment, is now likely to face pricing pressures and market share erosion. In response, the company has been exploring strategies such as partnerships and brand diversification to retain its foothold in the Indian market.
The broader impact of this shift is already visible in market sentiment, with pharmaceutical stocks witnessing an uptick amid optimism surrounding the generics boom. Analysts predict that India’s obesity drug market could expand substantially over the next decade, driven by increased affordability and growing awareness.
In conclusion, the expiry of Novo Nordisk’s semaglutide patent marks a significant milestone in India’s healthcare journey. While it promises enhanced access and affordability, its long-term success will depend on effective regulation, responsible usage, and sustained innovation within the pharmaceutical industry.
